Company profile for selectION

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

selectION, Inc. is a clinical-stage biopharmaceutical company developing novel peptide therapies for autoimmune diseases and selected cancer indications by targeting autoreactive, chronically activated T cells. The Company has established an efficient, unique technology platform to develop potent and highly selective peptide blockers for ion channels involved in various diseases. selectION is backed by SDL Ventures and Global ...
selectION, Inc. is a clinical-stage biopharmaceutical company developing novel peptide therapies for autoimmune diseases and selected cancer indications by targeting autoreactive, chronically activated T cells. The Company has established an efficient, unique technology platform to develop potent and highly selective peptide blockers for ion channels involved in various diseases. selectION is backed by SDL Ventures and Global Source Ventures. The Company is headquartered in San Diego, CA, USA, and has a subsidiary in Martinsried, Germany.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
655 India Street, Suite 204 San Diego, CA 92101
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmabiz.com/NewsDetails.aspx?aid=178647&sid=1

PHARMABIZ
23 Jun 2025

https://www.businesswire.com/news/home/20250410419625/en/Two-Large-Clinical-Trials-Find-a-Highly-Effective-Method-to-Select-Appropriate-Antibiotics-for-Patients-Hospitalized-With-Abdominal-or-Skin-and-Soft-Tissue-Infection

BUSINESSWIRE
10 Apr 2025

https://www.globenewswire.com/news-release/2025/02/06/3022442/0/en/GENFIT-Outlines-Anticipated-New-Clinical-Trial-Initiations-Development-Milestones-and-Data-Readouts-in-2025.html

GLOBENEWSWIRE
06 Feb 2025

https://www.globenewswire.com/news-release/2025/01/16/3010740/37244/en/Predictive-Oncology-Announces-Planned-European-Launch-of-its-ChemoFx-Treatment-Selection-Marker-and-Tumor-Profiling-Assay.html

GLOBENEWSWIRE
16 Jan 2025

https://www.globenewswire.com/news-release/2025/01/07/3005337/0/en/Erisyon-Awarded-2-2M-Grant-to-Develop-Diagnostic-for-Immuno-Oncology-Treatment-Selection.html

GLOBENEWSWIRE
07 Jan 2025

https://www.prnewswire.com/news-releases/apha-announces-schondelmeyer-as-the-2025-remington-honor-medal-recipient-302330680.html

PR NEWSWIRE
12 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty